{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:33:24Z","timestamp":1761964404626},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,6,30]],"date-time":"2012-06-30T00:00:00Z","timestamp":1341014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s00280-012-1910-2","type":"journal-article","created":{"date-parts":[[2012,6,29]],"date-time":"2012-06-29T02:45:15Z","timestamp":1340937915000},"page":"271-276","source":"Crossref","is-referenced-by-count":13,"title":["Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902"],"prefix":"10.1007","volume":"70","author":[{"given":"Young Hak","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Tomii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Masago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harukazu","family":"Yoshimatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koujirou","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Mio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Tomioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiaki","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,30]]},"reference":[{"key":"1910_CR1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","volume":"311","author":"Non-small Cell Lung Cancer Collaborative Group","year":"1995","unstructured":"Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899\u2013909","journal-title":"BMJ"},{"key":"1910_CR2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92\u201398","journal-title":"N Engl J Med"},{"key":"1910_CR3","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1200\/JCO.2009.23.5622","volume":"27","author":"CG Azzoli","year":"2009","unstructured":"Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2009) American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251\u20136266","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"1910_CR4","doi-asserted-by":"crossref","first-page":"ii39","DOI":"10.1093\/annonc\/mdn081","volume":"19","author":"G D\u2019Addario","year":"2008","unstructured":"D\u2019Addario G, Felip E (2008) Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2):ii39\u2013ii40","journal-title":"Ann Oncol"},{"key":"1910_CR5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1634\/theoncologist.6-4-363","volume":"6","author":"AR Hanauske","year":"2001","unstructured":"Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001) Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6:363\u2013373","journal-title":"Oncologist"},{"key":"1910_CR6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrd1528","volume":"3","author":"M Muhsin","year":"2004","unstructured":"Muhsin M, Gricks C, Kirkpatrick P (2004) Pemetrexed disodium. Nat Rev Drug Discov 3:825\u2013826","journal-title":"Nat Rev Drug Discov"},{"key":"1910_CR7","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543\u20133551","journal-title":"J Clin Oncol"},{"key":"1910_CR8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1634\/theoncologist.2008-0232","volume":"14","author":"G Scagliotti","year":"2009","unstructured":"Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA (2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14:253\u2013263","journal-title":"Oncologist"},{"key":"1910_CR9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/JTO.0b013e3181f7c6d4","volume":"6","author":"G Scagliotti","year":"2011","unstructured":"Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, Simms L, Fossella F, Sugarman K, Belani CP (2011) Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 6:64\u201370","journal-title":"J Thorac Oncol"},{"issue":"Suppl 5","key":"1910_CR10","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdq189","volume":"21","author":"G D\u2019Addario","year":"2010","unstructured":"D\u2019Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E (2010) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v116\u2013v119","journal-title":"Ann Oncol"},{"key":"1910_CR11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/bjc.1997.509","volume":"76","author":"Y Ando","year":"1997","unstructured":"Ando Y, Minami H, Saka H, Ando M, Sakai S, Shimokata K (1997) Adjustment of creatinine clearance improves accuracy of Calvert\u2019s formula for carboplatin dosing. Br J Cancer 76:1067\u20131071","journal-title":"Br J Cancer"},{"key":"1910_CR12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1910_CR13","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2008.20.9114","volume":"27","author":"BH Gr\u00f8nberg","year":"2009","unstructured":"Gr\u00f8nberg BH, Bremnes RM, Fl\u00f8tten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Toll\u00e5li T, Wammer F, Aaseb\u00f8 U, Sundstr\u00f8m S (2009) Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27:3217\u20133224","journal-title":"J Clin Oncol"},{"key":"1910_CR14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ctrv.2010.12.007","volume":"37","author":"YH Kim","year":"2011","unstructured":"Kim YH, Mishima M (2011) Maintenance chemotherapy for non-small-cell lung cancer. Cancer Treat Rev 37:505\u2013510","journal-title":"Cancer Treat Rev"},{"key":"1910_CR15","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(09)61433-1","volume":"374","author":"T Ciuleanu","year":"2009","unstructured":"Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374:432\u2013440","journal-title":"Lancet"},{"key":"1910_CR16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"L Paz-Ares","year":"2012","unstructured":"Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C (2012) Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13:247\u2013255","journal-title":"Lancet Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1910-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-012-1910-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1910-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:11:22Z","timestamp":1559023882000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-1910-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,30]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["1910"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-1910-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,30]]}}}